198 related articles for article (PubMed ID: 34680970)
21. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer.
Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C
Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
24. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
25. CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-α) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE).
Burton LJ; Hawsawi O; Sweeney J; Bowen N; Hudson T; Odero-Marah V
PLoS One; 2019; 14(4):e0214844. PubMed ID: 30964885
[TBL] [Abstract][Full Text] [Related]
26. HOXB7 Overexpression Leads Triple-Negative Breast Cancer Cells to a Less Aggressive Phenotype.
de Bessa Garcia SA; Araújo M; Pereira T; Freitas R
Biomedicines; 2021 May; 9(5):. PubMed ID: 34063128
[TBL] [Abstract][Full Text] [Related]
27. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
28. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
29. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract][Full Text] [Related]
30. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
32. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
[TBL] [Abstract][Full Text] [Related]
33. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
34. E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer.
Jusino S; Rivera-Rivera Y; Chardón-Colón C; Ruiz-Justiz AJ; Vélez-Velázquez J; Isidro A; Cruz-Robles ME; Bonilla-Claudio M; Armaiz-Pena GN; Saavedra HI
Exp Biol Med (Maywood); 2021 Oct; 246(19):2057-2071. PubMed ID: 34365840
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
Damiano V; Brisotto G; Borgna S; di Gennaro A; Armellin M; Perin T; Guardascione M; Maestro R; Santarosa M
Genes Chromosomes Cancer; 2017 Feb; 56(2):147-158. PubMed ID: 27717206
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
Byun WS; Kim WK; Yoon JS; Jarhad DB; Jeong LS; Lee SK
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244385
[TBL] [Abstract][Full Text] [Related]
38. δEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells.
Fukagawa A; Ishii H; Miyazawa K; Saitoh M
Cancer Med; 2015 Jan; 4(1):125-35. PubMed ID: 25315069
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
[TBL] [Abstract][Full Text] [Related]
40. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
